Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
ConclusionCombination BMS-986,205 and nivolumab showed a manageable safety profile with durable benefit as first-line therapy in a meaningful subset of advanced HCC patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Children | Drugs & Pharmacology | Hepatitis | Hepatocellular Carcinoma | Investigational New Drugs | Liver Cancer | Oral Cancer | Pancreatitis | Study | Toxicology